3-(benzo[d][1,3]dioxol-5-yl)-1H-pyrazol-5-amine | 208519-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 3-(benzo[d][1,3]dioxol-5-yl)-1H-pyrazol-5-amine
• 英文别名: 5-amino-3-(1,3-benzodioxol-5-yl)-1H-pyrazole；5-benzo[1,3]dioxol-5-yl-2H-pyrazol-3-ylamine；3-(1,3-benzodioxol-5-yl)-1H-pyrazol-5-amine；5-(1,3-benzodioxol-5-yl)-1H-pyrazol-3-amine
• CAS: 208519-15-7
• 化学式: C₁₀H₉N₃O₂
• 分子量: 203.2
• InChiKey: AKOLIWNDJVYUDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  73.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-(4-ethylpiperazin-1-yl)benzoate 、 3-(benzo[d][1,3]dioxol-5-yl)-1H-pyrazol-5-amine 在 三甲基铝 作用下， 以 甲苯 为溶剂， 反应 10.0h， 以31%的产率得到N-(3-(benzo[d][1,3]dioxol-5-yl)-1H-pyrazol-5-yl)-4-(4-ethylpiperazin-1-yl)benzamide
  参考文献：
  名称：

  Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model

  摘要：

  FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients. Recently, FLT3 inhibitors have been approved for AML therapy. Herein, a series of new compounds with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD. Compound 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line. Furthermore, the apoptosis and downregulation of P-STAT5 were also observed in tumor cells extracted from the MV411 cell xenografts model upon compound 46 treatment. Compound 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo. Compound 46 showed no toxicity to the viscera of mice and caused no decrease in body weight of mice. In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compound 46 was worthy of further development as potential drug candidate to treat AML (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.05.021
• 作为产物：
  描述：

  (Z)-3-Benzo[1,3]dioxol-5-yl-3-bromo-2-ethylsulfanyl-acrylonitrile 在 双氧水 、 一水合肼 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 8.33h， 生成 3-(benzo[d][1,3]dioxol-5-yl)-1H-pyrazol-5-amine
  参考文献：
  名称：

  A convenient synthesis of 3- and 5-amino-1H-pyrazoles via 3(5)-amino-4-(ethylsulfinyl)-1H-pyrazole desulfinylation

  摘要：

  Syntheses of 5-amino-3-aryl- and 3-amino-5-aryl-1H-pyrazoles from beta-bromo-alpha-(ethylsulfanyl)cinnamonitrile are described. The beta-bromo-alpha-(ethylsulfanyl) cinnamonitriles were oxidized with H(2)O(2) to the corresponding beta-bromo-alpha-(ethylsulfinyl) cinnamonitriles. Subsequent treatment of the resulting sulfoxides with hydrazine hydrate or methylhydrazine followed by hydrochloric acid hydrolysis afforded 5-amino-3-aryl- and 3-amino-5-aryl-1H-pyrazoles, respectively, in good yields.

  DOI：

  10.1515/hc.2011.026

文献信息

• Methods of treating conditions associated with an EDG-4 receptor
  申请人：Solow-Cordero David

  公开号：US20050113283A1

  公开（公告）日：2005-05-26

  The present invention provides a method of modulating an Edg-4 receptor mediated biological activity in a cell. A cell expressing the Edg-4 receptor is contacted with a modulator of an Edg-4 receptor sufficient to modulate the Edg-4 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-4 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-4 receptor is administered to the subject.

  本发明提供了一种调节细胞中Edg-4受体介导的生物活性的方法。将表达Edg-4受体的细胞与足以调节Edg-4受体介导的生物活性的调节剂接触。在另一个方面，本发明提供了一种调节受体Edg-4介导的生物活性的方法。向受体施用治疗有效量的Edg-4受体调节剂。
• 含氧杂环取代唑类化合物及其用途
  申请人：中国药科大学

  公开号：CN110835336B

  公开（公告）日：2022-10-04

  本发明涉及药物化学领域，公开了含氧杂环取代唑类化合物及其用途。具体涉及含氧杂环取代唑类化合物、它们的制备方法、含有这些化合物的药用组合物以及它们的医疗用途，特别是作为FMS样酪氨酸激酶3抑制剂的用途。
• PYRAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0945438A1

  公开（公告）日：1999-09-29

  The present invention relates to a compound represented by the general formula [I]: wherein A and B rings are ortho-condensed to each other, A ring represents an aromatic carbocyclic or heterocyclic ring and B ring represents an aliphatic four- to seven-membered carbocyclic or nitrogen-containing heterocyclic ring, said nitrogen atom being possible to present at only the position where the A ring is condensed; Ar represents an aromatic carbocyclic or heterocyclic ring group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aromatic carbocyclic ring groups; and R represents a substituent selected from the group consisting of a halogen atom and nitro, lower alkyl, lower alkoxy, aromatic carbocyclic ring groups and a carbonyl group having an aromatic carbocyclic ring group, or a hydrogen atom, provided that when the group represented by is the group represented by Ar is not a phenyl group nor a 4-chlorophenyl group, or its salt, a method for its preparation as well as an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.

  本发明涉及通式[I]代表的化合物： 其中 A 环和 B 环彼此正交缩合，A 环代表芳香族碳环或杂环，B 环代表脂肪族四至七元碳环或含氮杂环，所述氮原子可能仅存在于 A 环缩合的位置；Ar 代表芳香碳环或杂环基团，其取代基可选自由卤素原子、低级烷基、低级烯基、低级卤代烷基、低级烷氧基、低级烷硫基、低级烷氨基、低级二烷基氨基和芳香碳环基团组成的组；和 R 代表选自卤素原子和硝基、低级烷基、低级烷氧基、芳香族碳环基团和具有芳香族碳环基团的羰基或氢原子的取代基，条件是当由 代表的基团 Ar 不是苯基，也不是 4-氯苯基、 或其盐，其制备方法以及治疗暴食症、肥胖症或糖尿病的药物，其活性成分均包含该物质。
• NOVEL UREA DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0955293A1

  公开（公告）日：1999-11-10

  The present invention relates to a compound represented by the general formula [I]: wherein A represents a nitrogen atom or a group represented by C-R5; Ar1 represents an aryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl and lower haloalkyl groups; Ar2 represents an aryl or heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aryl groups; R1 represents a hydrogen atom, a lower alkyl group or a bond formed by linking to R5; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and each represents a hydrogen atom or a lower alkyl group, or R3 and R4 are linked to each other to form an alkylene group containing 2 to 4 carbon atoms which may have a lower alkyl group; and R5 represents a hydrogen atom or a hydroxyl, lower alkyl or lower alkoxy group or a bond formed by linking to R1, or its salt, a process for its preparation and an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.

  本发明涉及通式[I]所代表的化合物： 其中A代表氮原子或由C-R5代表的基团；Ar1代表芳基，其取代基可选自卤素原子和低级烷基及低级卤代烷基组成的组；Ar2代表芳基或杂芳基，其取代基可选自卤素原子和低级烷基、低级烯基、低级卤代烷基、低级烷氧基、低级烷硫基、低级烷基氨基、低级二烷基氨基和芳基组成的组；R1 代表氢原子、低级烷基或与 R5 连接形成的键；R2 代表氢原子或低级烷基；R3 和 R4 可以相同或不同，且各自代表氢原子或低级烷基，或 R3 和 R4 相互连接形成含 2 至 4 个碳原子的亚烷基，该亚烷基可能具有低级烷基；以及 R5 代表氢原子或羟基、低级烷基或低级烷氧基或与 R1 连接形成的键、 或其盐类，其制备方法和治疗贪食症、肥胖症或糖尿病的制剂，其活性成分包括它。
• UREA DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0955293B1

  公开（公告）日：2003-03-19